Andreas Brueckner

833 total citations
12 papers, 356 citations indexed

About

Andreas Brueckner is a scholar working on Economics and Econometrics, Pulmonary and Respiratory Medicine and Toxicology. According to data from OpenAlex, Andreas Brueckner has authored 12 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Economics and Econometrics, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Toxicology. Recurrent topics in Andreas Brueckner's work include Renal cell carcinoma treatment (3 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers) and Cancer Genomics and Diagnostics (3 papers). Andreas Brueckner is often cited by papers focused on Renal cell carcinoma treatment (3 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers) and Cancer Genomics and Diagnostics (3 papers). Andreas Brueckner collaborates with scholars based in United States, Switzerland and Germany. Andreas Brueckner's co-authors include Brian Schwartz, Dirk Strumberg, D. Voliotis, O. Christensen, S. Seeber, Jeffrey W. Clark, Holger W. Hirte, Ahmad Awada, Lionel Van Holle and Jim Slattery and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

Andreas Brueckner

12 papers receiving 350 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andreas Brueckner United States 7 98 97 91 84 49 12 356
Birgitta Grundmark Sweden 13 98 1.0× 201 2.1× 113 1.2× 95 1.1× 89 1.8× 18 593
Alan M. Hochberg United States 10 38 0.4× 168 1.7× 119 1.3× 45 0.5× 41 0.8× 18 611
Lesley Wise United Kingdom 9 58 0.6× 69 0.7× 60 0.7× 219 2.6× 20 0.4× 12 480
Salvador Fudio Spain 10 59 0.6× 36 0.4× 86 0.9× 93 1.1× 62 1.3× 32 365
Paul Gougis France 13 81 0.8× 15 0.2× 96 1.1× 225 2.7× 22 0.4× 44 483
Kosalaram Goteti United States 13 41 0.4× 14 0.1× 134 1.5× 91 1.1× 46 0.9× 32 489
Femke M. de Man Netherlands 10 96 1.0× 18 0.2× 219 2.4× 245 2.9× 30 0.6× 19 539
Aditi Shendre United States 13 98 1.0× 15 0.2× 83 0.9× 27 0.3× 16 0.3× 29 442
Jennie Chang United States 4 45 0.5× 12 0.1× 50 0.5× 161 1.9× 12 0.2× 4 339
Shazia Ali United States 9 35 0.4× 17 0.2× 259 2.8× 216 2.6× 53 1.1× 15 756

Countries citing papers authored by Andreas Brueckner

Since Specialization
Citations

This map shows the geographic impact of Andreas Brueckner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Brueckner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Brueckner more than expected).

Fields of papers citing papers by Andreas Brueckner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Brueckner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Brueckner. The network helps show where Andreas Brueckner may publish in the future.

Co-authorship network of co-authors of Andreas Brueckner

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Brueckner. A scholar is included among the top collaborators of Andreas Brueckner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Brueckner. Andreas Brueckner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Kutlar, Abdullah, Andreas Brueckner, Julie Kanter, et al.. (2023). Safety Profile of Crizanlizumab 5.0 Mg/Kg in Sickle Cell Disease: Pooled Data from Clinical Trials. Blood. 142(Supplement 1). 1139–1139. 1 indexed citations
2.
Rodríguez, Lisa, et al.. (2022). Global Landscape of Benefit–Risk Considerations for Medicinal Products: Current State and Future Directions. Pharmaceutical Medicine. 36(4). 201–213. 1 indexed citations
3.
Wisniewski, A, Andrew Bate, Cédric Bousquet, et al.. (2016). Good Signal Detection Practices: Evidence from IMI PROTECT. Drug Safety. 39(6). 469–490. 106 indexed citations
4.
Crowe, Brenda, Christy Chuang‐Stein, Sally Lettis, & Andreas Brueckner. (2016). Reporting Adverse Drug Reactions in Product Labels. Therapeutic Innovation & Regulatory Science. 50(4). 455–463. 11 indexed citations
5.
Merz, Michael, et al.. (2014). Methodology to Assess Clinical Liver Safety Data. Drug Safety. 37(S1). 33–45. 29 indexed citations
6.
Procopio, Giuseppe, Joaquim Bellmunt, Janice P. Dutcher, et al.. (2013). Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. British Journal of Cancer. 108(2). 311–318. 41 indexed citations
7.
Crowe, Brenda, Andreas Brueckner, Charles M. Beasley, & Pandurang M. Kulkarni. (2013). Current Practices, Challenges, and Statistical Issues With Product Safety Labeling. Statistics in Biopharmaceutical Research. 5(3). 180–193. 8 indexed citations
8.
Lanas, Ángel, Denis M. McCarthy, Michael Voelker, et al.. (2011). Short-Term Acetylsalicylic Acid (Aspirin) Use for Pain, Fever, or Colds —Gastrointestinal Adverse Effects. Drugs in R&D. 11(3). 277–288. 37 indexed citations
9.
Bracarda, Sergio, C. Bokemeyer, Giuseppe Procopio, et al.. (2011). 718 SORAFENIB (SOR) DOSAGE PATTERNS IN OLDER PATIENTS (PTS) WITH ADVANCED RENAL CELL CARCINOMA (RCC): A SUBANALYSIS BY AGE OF AN INTEGRATED DATABASE OF 8 COMPANY-SPONSORED CLINICAL TRIALS. European Urology Supplements. 10(2). 229–229. 3 indexed citations
10.
11.
Hutson, Thomas E., Giuseppe Procopio, Bernard Escudier, et al.. (2010). Long-term sorafenib (SOR) safety profile in more than 700 patients (pts) with renal-cell carcinoma (RCC) treated for 12 to 42 months (mos).. Journal of Clinical Oncology. 28(15_suppl). 4614–4614. 3 indexed citations
12.
Strumberg, Dirk, Ahmad Awada, Holger W. Hirte, et al.. (2006). Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?. European Journal of Cancer. 42(4). 548–556. 115 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Birgitta Grundmark Breakdown of academic impact, for papers by Alan M. Hochberg Breakdown of academic impact, for papers by Lesley Wise Breakdown of academic impact, for papers by Salvador Fudio Breakdown of academic impact, for papers by Paul Gougis Breakdown of academic impact, for papers by Kosalaram Goteti Breakdown of academic impact, for papers by Femke M. de Man Breakdown of academic impact, for papers by Aditi Shendre Breakdown of academic impact, for papers by Jennie Chang Breakdown of academic impact, for papers by Shazia Ali
Rankless by CCL
2026